About The Study: Following landmark clinical trials and changes in guideline recommendations, self-reported primary prevention aspirin use decreased among older adults and adults with low atherosclerotic cardiovascular disease (ASCVD) risk for whom aspirin was not recommended, but also decreased among adults with higher ASCVD risk for whom aspirin may still be recommended. Despite these reductions, many patients with limited likelihood to benefit reported continuing to take aspirin.
Corresponding Author: To contact the corresponding author, Timothy S. Anderson, MD, MAS, email tsander@pitt.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.27333)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.27333?guestAccessKey=92514d49-ef8a-4a09-9ce1-7a4d3cefea53&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012225
JAMA